

Colorectal Cancer: A Minimalist Approach

Sandy Hwang Fang, MD, FACS, FASCRS Associate Professor

6th Annual Knight Cancer Network Symposium

DATE: March 18, 2022

Disclosures

Consultant for Intuitive when I was at Johns Hopkins Hospital.






Objectives

- 1. Robotic surgery in colorectal cancer
- 2. Watch and Wait Approach to Rectal Cancer



Robotic total mesorectal excision





Randomized Controlled Trial > JAMA. 2017 Oct 24;318(16):1569-1580.

doi: 10.1001/jama.2017.7219.

Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial

David Jayne ¹, Alessio Pigazzi ², Helen Marshall ³, Julie Croft ³, Neil Corrigan ³, Joanne Copeland ³, Phil Quirke ⁴, Nick West ⁴, Tero Rautio ⁵, Niels Thomassen ⁶, Henry Tilney ⁷, Mark Gudgeon ⁷, Paolo Pietro Bianchi ⁸, Richard Edlin ⁹, Claire Hulme ¹⁰, Julia Brown ³

- Randomized clinical trial: robotic-assisted vs conventional laparoscopic surgery => open conversion rates
 - 29 sites, 10 countries, 40 surgeons
 - Recruitment: 1/7/2011-9/30/2014
- 471 patients with rectal adenocarcinoma
 - Robotic assisted: 237 patients
 - Laparoscopic: 234 patients
- f/u: 30 days, 6 months
- No significant reduction in conversion to laparotomy



Randomized Controlled Trial > JAMA. 2017 Oct 24;318(16):1569-1580.

doi: 10.1001/jama.2017.7219.

Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial

David Jayne ¹, Alessio Pigazzi ², Helen Marshall ³, Julie Croft ³, Neil Corrigan ³, Joanne Copeland ³, Phil Quirke ⁴, Nick West ⁴, Tero Rautio ⁵, Niels Thomassen ⁶, Henry Tilney ⁷, Mark Gudgeon ⁷, Paolo Pietro Bianchi ⁸, Richard Edlin ⁹, Claire Hulme ¹⁰, Julia Brown ³

Table 3. Secondary End Points by Treatment Group

	No./Total No. (%)				
End Point	Conventional Laparoscopic Surgery	Robotic-Assisted Laparoscopic Surgery	Unadjusted Risk Difference (95% CI), %	Adjusted Odds Ratio (95% CI)ª	P Value
CRM+ ^b	14/224 (6.3)	12/235 (5.1)	1.2 (-3.1 to 5.4)	0.78 (0.35 to 1.76)	.56
Mesorectal area = mesorectal plane	173/223 (77.6)	178/233 (76.4)	1.2 (-6.5 to 8.9)	0.94 (0.56 to 1.57)	.14
Intraoperative complication	34/230 (14.8)	36/236 (15.3)	-0.5 (-6.0 to 7.0)	1.02 (0.60 to 1.74)	.94
Postoperative complication within 30 d of operation	73/230 (31.7)	78/236 (33.1)	-1.3 (-9.8 to 7.2)	1.04 (0.69 to 1.58)	.84
Postoperative complication >30 d and ≤6 mo after operation	38/230 (16.5)	34/236 (14.4)	2.1 (-4.5 to 8.7)	0.72 (0.41 to 1.26)	.25
Mortality within 30 d of operation ^c	2/230 (0.9)	2/236 (0.8)	0.02 (-1.7 to 1.7)	NA	NA

Abbreviations: CRM+, circumferential resection margin positivity; NA, not applicable.

- ^a Adjusted for sex, body mass index class, preoperative radiotherapy, intended procedure, and operating surgeon.
- ^b Defined as tumor cells within 1 mm of the circumferential resection margin on histological analysis.
- ^c Adjusted analysis was not performed for mortality within 30 days of operation due to the small number of events.



Clinical Trial > Ann Surg. 2018 Feb;267(2):243-251. doi: 10.1097/SLA.00000000002321.

Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial

Min Jung Kim¹, Sung Chan Park¹, Ji Won Park¹², Hee Jin Chang¹, Dae Yong Kim¹, Byung-Ho Nam³, Dae Kyung Sohn¹, Jae Hwan Oh¹

- Randomized 1:1: robotic vs laparoscopic
 - South Korea, 3 surgeons
 - Recruitment: 2/21/2012-3/11/2015
- Primary outcome: quality of TME
- 139 patients
 - Robotic: 66
 - Laparoscopic: 73



Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial

Min Jung Kim ¹, Sung Chan Park ¹, Ji Won Park ¹ ², Hee Jin Chang ¹, Dae Yong Kim ¹, Byung-Ho Nam ³, Dae Kyung Sohn ¹, Jae Hwan Oh ¹

Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial

Kim, Min Jung; Park, Sung Chan; Park, Ji Won; Chang, Hee Jin; Kim, Dae Yong; Nam, Byung-Ho; Sohn, Dae Kyung; Oh,

	RG $(n = 66)$	LG $(n = 73)$	P Nam, Byung-Ho; Sohn, Dae Kyung; Oh,
Tumor size, cm, median (range)	2.5 (0-6.0)	2.1 (0-11.0)	0.84 Jae Hwan
Number of harvested lymph nodes	2.5 (0-0.0)	2.1 (0-11.0)	
Median	18.0	15.0	minuto of ourger y207(2).210 201,
Range	7.0-59.0	4.0-40.0	February 2018.
<12, n (%)	6 (9,1)	19 (26.0)	0.009 doi: 10.1097/SLA.000000000002321
$\geq 12, n (\%)$	60 (90.9)	54 (74.0)	0.009 doi: 10.1097/SLA.00000000002321
≥ 12 , if (%) Tumor differentiation, n (%)	00 (90.9)	54 (74.0)	0.412
Well differentiated	9 (13.6)	8 (11.0)	0.412
Moderately differentiated	53 (80.3)	64 (86.2)	
Poorly differentiated	3 (4.6)	1 (1.4)	
Mucinous	1 (1.5)	0(1.4)	
Tumor Regression Grade Scale, n (%)*	1 (1.5)	0 (1.4)	0.99
1 unior Regression Grade Scale, II (%)	11 (16 7)	11 (15 1)	0.99
1	11 (16.7)	11 (15.1)	
2 3	28 (42.4) 8 (12.1)	31 (42.5) 10 (13.7)	
3 4			
	5 (7.6)	6 (8.2)	0.956
p/ypT classification, n (%)	5 (76)	6 (8 2)	0.956
TO	5 (7.6)	6 (8.2)	
Tis	2 (3.0)	4 (5.5)	
T1	8 (12.1)	7 (9.6)	
T2	17 (25.8)	18 (24.6)	
T3	30 (45.5)	36 (49.3)	
T4a	2 (3.0)	1 (1.4)	
T4b	2 (3.0)	1 (1.4)	0.710
p/ypN classification, n (%)			0.713
NO	46 (69.7)	56 (76.7)	
Nla	9 (13.7)	5 (6.9)	
N1b	7 (10.6)	6 (8.2)	
N1c	2 (3.0)	2 (2.7)	
N2a	2 (3.0)	3 (4.1)	
N2b	0 (0)	1 (1.4)	
Proximal resection margin, cm, median (range)	12.3 (4.7–35.8)	13.2 (6.8–29.0)	0.727
Distal resection margin, cm, median (range)	1.5 (0.04-6.7)	0.7 (0-2.5)	0.11
Radial resection margin, cm, median (range)	0.7 (0-2.5)	0.7 (0-1.8)	0.531
Circumferential resection margin, n (%)†			0.999
Positive ($\leq 1 \text{ mm}$)	4 (6.1)	4 (5.5)	
Negative (>1 mm)	61 (92.4)	68 (93.2)	
Quality of TME as rated by pathologist, n (%)			0.599
Complete	53 (80.3)	57 (78.1)	
Nearly complete	12 (18.2)	16 (21.9)	Postoperative Pathologic Outcomes
Incomplete	1 (1.5)	0 (0)	

*Data from patients with preoperative CRT or chemotherapy.

†One patient in each group had a peritonealized tumor.

CRT indicates chemoradiotherapy; TME, total mesorectal excision.





Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial

RG (n = 66)

Min Jung Kim ¹, Sung Chan Park ¹, Ji Won Park ¹ ², Hee Jin Chang ¹, Dae Yong Kim ¹, Byung-Ho Nam ³, Dae Kyung Sohn ¹, Jae Hwan Oh ¹

Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial

Kim, Min Jung; Park, Sung Chan; Park, Ji Won; Chang, Hee Jin; Kim, Dae Yong; Nam, Byung-Ho; Sohn, Dae Kyung; Oh, Jae Hwan

				Ino Huron
Tumor size, cm. median (range)	2.5 (0-6.0)	2.1.(0-11.0)		Jae Hwan
Number of harvested lymph nodes			0.04	Annals of Surgery267(2):243-251,
Median	18.0	15.0		February 2018.
Range	7.0-59.0	4.0-40.0		
<12, n (%)	6 (9.1)	19 (26.0)	0.009	doi: 10.1097/SLA.000000000002321
≥12, n (%)	60 (90.9)	54 (74.0)		
Tumor differentiation, n (%)			0.412	2
Well differentiated	9 (13.6)	8 (11.0)		
Moderately differentiated	53 (80.3)	64 (86.2)		
Poorly differentiated	3 (4.6)	1 (1.4)		
Mucinous	1 (1.5)	0 (1.4)		
Tumor Regression Grade Scale, n (%)*			0.99	
1	11 (16.7)	11 (15.1)		
2	28 (42.4)	31 (42.5)		
3	8 (12.1)	10 (13.7)		
4	5 (7.6)	6 (8.2)		
p/ypT classification, n (%)			0.956	5
TO	5 (7.6)	6 (8.2)		
Tis	2 (3.0)	4 (5.5)		
T1	8 (12.1)	7 (9.6)		
T2	17 (25.8)	18 (24.6)		
Т3	30 (45.5)	36 (49.3)		
T4a	2 (3.0)	1 (1.4)		
T4b	2 (3.0)	1 (1.4)		
p/ypN classification, n (%)			0.713	3
NO	46 (69.7)	56 (76.7)		
N1a	9 (13.7)	5 (6.9)		
N1b	7 (10.6)	6 (8.2)		
N1c	2 (3.0)	2 (2.7)		
N2a	2 (3.0)	3 (4.1)		
N2b	0 (0)	1 (1.4)		
Proximal resection margin, cm, median (range)	12.3 (4.7-35.8)	13.2 (6.8-29.0)	0.727	7
Distal resection margin, cm, median (range)	1.5(0.04-6.7)	0.7 (0-2.5)	0.11	
Radial resection margin, cm, median (range)	0.7 (0-2.5)	0.7 (0-1.8)	0.531	
Circumferential resection margin, n (%)†			0.999	
Positive ($\leq 1 \text{ mm}$)	4 (6.1)	4 (5.5)	0.000	
Negative (>1 mm)	61 (92.4)	68 (93.2)		
Quality of TME as rated by pathologist, n (%)			0.599)
Complete	53 (80.3)	57 (78.1)	0.077	
Nearly complete	12 (18.2)	16 (21.9)		Destan enstire Dath alogic Outsom
Incomplete	12(10.2) 1(1.5)	0 (0)		Postoperative Pathologic Outcome
meempiete	1 (1.5)	0 (0)		

LG (n = 73)

*Data from patients with preoperative CRT or chemotherapy.

†One patient in each group had a peritonealized tumor.

CRT indicates chemoradiotherapy; TME, total mesorectal excision.



Watch and Wait: Rectal Cancer Organ Preservation











Table 2 Memorial Sloan Kettering Regression Schema

	Complete Response	Near Complete Response	Incomplete Response
Endoscopy	Flat, white scar Telangiectasia No ulcer No nodularity	Irregular mucosa Small mucosal nodules or minor mucosal abnormality Superficial ulceration Mild persisting erythema of the scar	Visible tumor
Digital Rectal Exam	Normal	Smooth induration or minor mucosal abnormalities	Palpable tumor nodules
MRI-T2W	Only dark T2 signal, no intermediate T2 signal	Mostly dark T2 signal, some remaining intermediate signal	More intermediate than dark T2 signal, no T2 scar
	AND	AND/OR	AND/OR
	No visible lymph nodes	Partial regression of lymph nodes	No regression of lymph nodes
MRI-DW	No visible tumor on B800-B1000 signal	Significant regression of signal on B800-B1000	Insignificant regression of signal on B800-B1000
	AND/OR	AND/OR	AND/OR
	Lack of or low signal on ADC map Uniform, linear signal in wall above tumor is ok	Minimal or low residual signal on ADC map	Obvious low signal on ADC map




Clinical Incomplete Response





Clinical Complete Response





Controlled Clinical Trial > Clin Colorectal Cancer. 2021 Sep;20(3):e185-e193. doi: 10.1016/i.clcc.2021.03.003. Epub 2021 Apr 7.

Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial

Hyun Kim¹, Katrina Pedersen², Jeffrey R Olsen³, Matthew G Mutch⁴, Re-I Chin⁵, Sean C Glasgow⁴, Paul E Wise⁴, Matthew L Silviera⁴, Benjamin R Tan², Andrea Wang-Gillam², Kian-Huat Lim², Rama Suresh², Manik Amin², Yi Huang⁵, Lauren E Henke⁵, Haeseong Park², Matthew A Ciorba⁶, Shahed Badiyan⁵, Parag J Parikh⁷, Michael C Roach⁸, Steven R Hunt³

- Treatment
 - 25 Gy in 5 fractions
 - FOLFOX x 8 cycles or CAPOX x 5 cycles
- June 2016-March 2019: 19 patients
- Treatment with SCRT and chemotherapy resulted in high cCR rate, intact anorectal function, and no severe late effects




Surveillance Protocol: NCCN

(In addition to CT C/A/P, CEA, colonoscopy)

- DRE
- Proctoscopy
 - Every 3-4 months x 2 years
 - Then every 6 months for a total of 5 years
- Rectal cancer protocol MRI
 - Every 6 months for at least 3 years to monitor for extraluminal local recurrence
 - Then annually for a total of 5 years (OHSU)



ReSARCh (Rectal Sparing Approach after preroperative Radio-and/or Chemotherapy)






Organ Preservation in Rectal Adenocarcinoma (OPRA): ongoing

 Objective: Phase II randomized controlled trial, multi-institutional: total neoadjuvant therapy and selective non-operative management in locally advanced rectal cancer





*Patients with tumor progression at the interval evaluation will be treated according to standard of care.

Fig. 1 Trial schema. MSKCC-based multi-institutional, Phase II trial schema underway to test the feasibility of incorporating a NOM approach to the multimodality treatment of rectal cancer. This study will evaluate the 3-year DFS in LARC patients treated with CRT plus induction or consolidation chemotherapy and TME or NOM (https://clinicaltrials.gov/ct2/show/NCT02008656?term=NCT02008656&rank=1)



Thank you! Questions??